[1] World Health Organization: Programmes and projects: Media centre: Fact sheet N 297 (February 2009). Available: http://www.who.int/ mediacentre/factsheets/fs297/en/print.html [accessed July 27, 2010].

[2] C. E. Holmes, H. B. Muss, “Diagnosis and treatment of breast cancer in the elderly,” CA Cancer J. Clin. 53, 227–244 (2003).

[3] K. S. Anderson, “Tumor vaccines for breast cancer,” Cancer Invest. 27, 361–368 (2009).

[4] W. R. Chen, R. L. Adams, R. Carubelli, R. E. Nordquist, “Laser-photosensitizer assisted immunotherapy: A novel modality in cancer treatment,” Cancer Lett. 115, 25–30 (1997).

[5] W. R. Chen, H. Liu, J. W. Ritchey, K. E. Bartels, M. D. Lucroy, R. E. Nordquist, “Effect of different components of laser immunotherapy in treatment of metastatic tumors in rats,” Cancer Res. 62, 4295– 4299 (2002).

[6] W. R. Chen, W.-G. Zhu, J. R. Dynlacht, H. Liu, R. E. Nordquist, “Long-term tumor resistance induced by laser photo-immunotherapy,” Int. J. Cancer 81, 808–812 (1999).

[7] M. F. Naylor, W. R. Chen, T. K. Teague, L. Perry, R. E. Nordquist, “In situ photo-immunotherapy: A tumor-directed treatment modality for melanoma,” Br. J. Dermatol. 155, 1287–1292 (2006).

[8] X. Li, M. F. Naylor, R. E. Nordquist, T. T. Kent, H. C. Anthony, M. Cynthia, W. R. Chen, “Clinical effects of in situ photoimmunotherapy on late-stage melanoma patients: A preliminary study,” Cancer Biol. Ther. (2010), in press.

[9] S. E. Singletary, J. L. Connolly, “Breast cancer staging: Working with the sixth edition of the AJCC Cancer Staging Manual,” CA Cancer J. Clin. 56, 37–47 (2006).

[10] US Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis: Common terminology criteria for adverse events v3.0 (CTCAE). Available: http://ctep.cancer.gov/ protocolDevelopment/electronic applications/docs/ ctcaev3.pdf [accessed September 28, 2009].

[11] E. A. Eisenhauer, P. Therasse, J. Bogaerts, L. H. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, L. Rubinstein, L. Shankar, L. Dodd, R. Kaplan, D. Lacombe, J. Verweij, “New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1),” Eur. J. Cancer 45, 228–247 (2009).

[12] MBC Advocacy Working Group, “Bridging gaps, expanding outreach: Metastatic Breast Cancer Advocacy Working Group Consensus Report,” Breast 18, 273–275 (2009).

[13] W. R. Chen, A. K. Singhal, H. Liu, R. E. Nordquist, “Laser immunotherapy induced antitumor immunity and its adoptive transfer,” Cancer Res. 61, 459– 461 (2001).

[14] W. R. Chen, H. Liu, J. A. Nordquist, R. E. Nordquist, “Tumor cell damage and leukocyte infiltration after laser immunotherapy treatment,” Lasers Med. Sci. 15, 43–48 (2000).

[15] W. R. Chen, S. W. Jeong,M. D. Lucroy, R. F.Wolf, E. W. Howard, H. Liu, R. E. Nordquist, “Induced anti-tumor immunity against DMBA-4 metastatic mammary tumors in rats using a novel approach,” Int. J. Cancer 107, 1053–1057 (2003).

[16] W. R. Chen, M. Korbelik, K. E. Bartels, H. Liu, J. Sun, R. E. Nordquist, “Enhancement of laser cancer treatment by a chitosan-derived immunoadjuvant,” Photochem. Photobiol. 81, 190–195 (2005).